ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
Phase 1
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- Drug: ARV-471 in combination with Everolimus
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Arvinas Estrogen Receptor, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05501769
- Locations
- 🇪🇸
Clinical Trial Site, Valencia, Spain
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
Phase 1
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- Drug: ARV-471 in combination with palbociclib (IBRANCE®)
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Arvinas Estrogen Receptor, Inc.
- Target Recruit Count
- 217
- Registration Number
- NCT04072952
- Locations
- 🇺🇸
Clinical Trial Site, Seattle, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath